Search the Newsreel

Should Halozyme’s New ENHANZE–Incyte Oncology Pact Reshape How HALO Investors View Its Royalty Model?

Halozyme Therapeutics announced a new global collaboration with Incyte, leveraging its ENHANZE drug delivery technology for an oncology program. This partnership aims to broaden Halozyme's royalty streams in blood cancers, adding to its existing collaborations. While this new deal reinforces Halozyme's strategy of expanding …

Halozyme’s Partnerships, Earnings Growth See Shares Near All-Time Highs

Halozyme Therapeutics, Inc. (HALO) shares have seen significant gains, rising 539% since March 2014 and 52% this year, driven by strong institutional buying and robust fundamentals. The company's recent earnings report showed record revenue and a raised 2026 guidance, indicating continued growth prospects for …

Did Halozyme’s (HALO) New Incyte Enhanze Deal Just Redefine Its Precision Oncology Royalty Engine?

Halozyme Therapeutics recently entered a global partnership and licence agreement with Incyte to apply its Enhanze drug delivery technology to additional subcutaneous formulations of INCA033989, a monoclonal antibody targeting mutant calreticulin in myeloproliferative neoplasms. This collaboration highlights how Halozyme can plug its Enhanze platform …

Benchmark reiterates Halozyme stock Buy rating on Incyte deal By Investing.com

Benchmark reiterated its Buy rating and $90 price target for Halozyme Therapeutics following the company's licensing agreement with Incyte Pharmaceuticals. The deal involves Halozyme's Enhanze drug development technology to create subcutaneous formulations of Incyte's INCA033989. Halozyme will receive an upfront payment, potential development milestones, …

Halozyme Therapeutics (HALO) Lands Incyte Deal On A Valuation That Still Looks Undervalued

Halozyme Therapeutics recently partnered with Incyte, using its Enhanze technology for subcutaneous formulations. Despite a 12.46% share price increase over 30 days and long-term gains, the stock appears undervalued, with analysts estimating a fair value of $83.90 compared to its current $77.09. However, its …

Halozyme in deal with Incyte to use Enhanze technology for neoplasms candidate

[Businessmen shaking hands] Andy Andrews * Halozyme (HALO [https://seekingalpha.com/symbol/HALO]) has signed a global collaboration and license agreement with Incyte (INCY [https://seekingalpha.com/symbol/INCY]) to potentially use the former's Enhanze drug delivery technology with the latter's INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody for mutCALR-expressing myeloproliferative …

Halozyme partners with Incyte on drug delivery technology By Investing.com

Halozyme Therapeutics Inc. has announced a global collaboration and license agreement with Incyte to develop subcutaneous formulations of INCA033989 using Halozyme's ENHANZE drug delivery technology. Halozyme will receive an upfront payment and is eligible for additional milestone payments and royalties. The partnership aims to …

Halozyme Announces Global Collaboration and License Agreement with Incyte to Support the Development of Subcutaneous Formulations of INCA033989 Using its ENHANZE® Technology

Halozyme Therapeutics, Inc. (Nasdaq: HALO) has entered into a global collaboration and license agreement with Incyte (Nasdaq: INCY) to develop subcutaneous formulations of INCA033989 using Halozyme's ENHANZE® drug delivery technology. This collaboration aims to improve the treatment experience for patients with mutCALR-expressing myeloproliferative neoplasms …

Technical Reactions to HALO Trends in Macro Strategies

This article from Stock Traders Daily discusses technical reactions to HALO trends in macro strategies, focusing on Halozyme Therapeutics Inc. (NASDAQ: HALO). It highlights conflicting sentiment across different time horizons, suggesting choppy market conditions for the stock. The analysis provides specific trading strategies (Position, …

Halozyme Therapeutics (HALO) Gets A Lift As Darzalex Faspro Trial Improves Survival

Halozyme Therapeutics (HALO) saw a positive impact from a partner trial for Darzalex Faspro, which uses Halozyme's ENHANZE technology. The trial reported significant survival benefits for multiple myeloma patients, highlighting the value of ENHANZE in improving established cancer therapies. This success reinforces Halozyme's business …

Halozyme Therapeutics Q1 2026 Earnings Review | HALO Stock - News and Statistics

Halo Minerals Plc ORD GBP0.001 share price | HALO

Halo Minerals begins trading after £20m AIM float

Halo Minerals targets AIM listing to fund Chile copper tailings

Dividend Stocks Are Getting a Boost From the HALO Trade. Can It Last?